Non-Surgical Skin Tightening

Non-surgical skin tightening using FDA-cleared radiofrequency and ultrasound-based technologies. Targets facial laxity, jowls, neck, and body areas with no surgery or downtime at Cutis, Pacific Plaza.

Cutis Medical Laser Clinics offers a range of FDA-cleared non-surgical skin tightening treatments using radiofrequency (RF) and focused ultrasound technologies, selected for their evidence base by Medical Director Dr. Sylvia Ramirez. These treatments address skin laxity, early jowling, brow ptosis, neck looseness, and body skin firmness — concerns commonly presenting in patients aged 35 and above who want measurable structural improvement without surgical risk or downtime. Radiofrequency-based skin tightening delivers controlled heat energy to the dermal and subdermal layers, stimulating fibroblasts to produce new collagen and elastin. The resulting tissue remodelling gradually tightens and lifts the skin over a 2–6 month period post-treatment. RF microneedling combines fractional microneedle penetration with RF energy delivery directly into the dermis, producing greater collagen induction with precision depth control — effective for both skin tightening and acne scar improvement. Focused ultrasound (HIFU/Ultherapy-type) treatments target the SMAS (superficial musculoaponeurotic system) layer — the same tissue plane addressed in surgical facelifts — delivering acoustic energy precisely to depths of 1.5 mm, 3 mm, and 4.5 mm. This selectively heats the SMAS and deep dermis without affecting the skin surface, triggering a natural regenerative response with gradual lifting and tightening that develops over 3–6 months. The clinical effect is a measurable brow lift, jawline definition, and neck tightening. At Cutis, all skin tightening treatments are preceded by a physician assessment to evaluate degree of laxity, skin quality, and expected response. Results are cumulative with repeat sessions, and maintenance treatments 1–2 times per year are recommended. The clinic's evidence-based approach ensures device and energy parameter selection is driven by clinical protocols rather than sales targets.